Here's Why Celldex Therapeutics' Stock Got Crushed Today

What's happening : Celldex Therapeutics , a clinical-stage oncology company, saw its shares drop by 25% on exceptional volume this morning on the back of its second-quarter earnings release. As a developmental-stage biotech with a cash runway that reportedly extends through 2017 , investors probably weren't worried so much about the company's financials, but rather the regulatory update for Rintega, an experimental vaccine designed to elicit a powerful immune response against EGFR vIII -positive brain tumors.

Unfortunately, management stated in the accompanying conference call that they now believe the U.S. Food and Drug Administration is unwilling to review the vaccine on an accelerated basis, based on its impressive midstage study dubbed "ReAct", citing the study's small sample size as a major area of concern. So, instead, the FDA apparently prefers to wait until Rintega's late-stage trial, ACT IV, wraps up in late 2016 before agreeing to a formal regulatory review. That said, the discussions on Rintega's regulatory pathway are still preliminary at this point, and nothing is set in stone as of yet.

Why it's happening : At the 2015 American Society of Clinical Oncology meeting earlier this year, Celldex updated investors on Rintega's midstage trial, where the vaccine reportedly led to a minor clinical benefit in terms of progression-free survival but essentially doubled overall survival (30% vs. 15%) at the six-month mark when used in conjunction with Avastin, per the intent-to-treat analysis, compared to patients on Avastin alone. Patients taking the combo of Avastin plus Rintega were also able to reduce the amount of steroids they were taking, according to the company.

Because this form of brain cancer is particularly aggressive, always fatal, and there are no decent treatment options available to patients at the moment, the market was apparently overly optimistic about the prospects of an accelerated approval.

Given that Rintega has already shown demonstrably more clinical benefit in this patient population than the current standard of care, albeit in small studies, the vaccine looks, to me, like it has a better than average shot at becoming an important new treatment option for this deadly disease. As such, I think investors with a high tolerance for risk and volatility may want to consider picking up some shares in this promising biopharma after this hefty pullback.

The next billion-dollar iSecret

The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .

The article Here's Why Celldex Therapeutics' Stock Got Crushed Today originally appeared on

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Celldex Therapeutics. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More